Ulipristal acetate, a selective progesterone receptor modulator, induces cell death via inhibition of STAT3/CCL2 signaling pathway in uterine sarcoma

• Published in: Biomedicine & pharmacotherapy 2023-12, Vol.168, p.115792-115792, Article 115792
• Main Authors: Hwang, Jae Ryoung, Cho, Young-Jae, Ryu, Ji-Yoon, Choi, Ju-Yeon, Choi, Jung-Joo, Sa, Jason K., Kim, Hyun-Soo, Lee, Jeong-Won
• Format: Article
• Language: English
• Subjects: Patient-derived xenograft model (PDX); Selective progesterone receptor modulators; STAT3/CCL2; Ulipristal acetate (UPA); Uterine leiomyosarcoma
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2023.115792

Ulipristal acetate (UPA) is a selective progesterone receptor modulator and is used for the treatment of uterine leiomyoma (a benign tumor). Uterine sarcoma which is highly malignant cancer with a poor prognosis is clinically resembled with uterine leiomyoma. There has been no experimental research on the effect of UPA on uterine sarcoma. In this study, we examined the efficacy of UPA in uterine sarcoma with in vitro and in vivo animal models. Cytotoxicity of UPA was determined in uterine sarcoma cell lines (MES-SA, SK-UT-1, and SK-LMS-1). Apoptotic genes and signaling pathways affected by UPA were analyzed by complementary DNA (cDNA) microarray of uterine sarcoma cell lines and western blot, respectively. An in vivo efficacy of UPA was examined with uterine sarcoma cell line- and patient-derived xenograft (PDX) mice models. UPA inhibited cell growth in uterine sarcoma cell lines and primary culture cells from a PDX mouse (PDX-C). cDNA microarray analysis revealed that CCL2 was highly down-regulated by UPA. Phosphorylation and the total expression of STAT3 were inhibited by UPA. UPA also inhibited CCL2 and STAT3 in PDX-C. The inhibitory effect of UPA had not changed in the overexpression of PR and treatment of progesterone. In vivo efficacy studies with cell line-derived xenografts and a PDX model with leiomyosarcoma, a typical uterine sarcoma, demonstrated that UPA significantly decreased tumor growth. UPA had significant anti-tumor effects in uterine sarcoma through the inhibition of STAT3/CCL2 signaling pathway and might be a potential therapeutic agent to treat this disease. [Display omitted] •Uterine leiomyosarcoma (uLMS) is highly aggressive malignant cancer.•Ulipristal acetate (UPA) has been used to reduce the growth of uterine leiomyoma.•Uterine leiomyoma is hardly discriminated against uLMS without myomectomy.•UPA inhibits cell proliferation by targeting the STAT3/CCL2 signaling pathway.•UPA inhibits tumor growth in uLMS cell lines xenograft and PDX mouse models.